ImmuDyne Announces Addition of $1.25 Million Retail

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ImmuDyne Announces Addition of $1.25 Million Retail Inventory of Its New Dietary Supplements; iNR Wellness, iNR Wellness MD, and iNR Strength

MT. KISCO, N.Y., Sept. 26, 2013 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) announced today that it has produced inventory for its new dietary supplement lines for sale; iNR Wellness™, iNR Wellness MD™, and iNR Strength™, with a retail value of over $1.25 million.

The products will be promoted through physician networks, fitness experts, online advertising, test-market television sponsorships, and social media. The products will be available to consumers through an online store this October and the campaigns will launch later this year.

Karen Kingston, Chief Marketing Officer, stated, "The iNR Wellness, iNR Wellness MD, and iNR Strength product lines have been custom formulated for consumers depending on their immune support needs. For example, iNR Strength is an ideal supplement for consumers who are more fitness goal oriented and will be represented by fitness experts and organizations. iNR Wellness MD is a clinically researched, doctor recommended supplement for consumers who may have weakened immune health due to illness or advancing age, and will be distributed through physician practices."

Mark McLaughlin, President & CEO, added, "ImmuDyne is particularly pleased with the progress we have made with private practice doctors and physician networks as they will be key partners in the launch of the iNR Wellness MD line. In addition, the launch of the iNR Wellness and iNR Strength products this fall provides the Company with a solid foundation to meet the 2014 revenue forecast put forth in our 18-month marketing plan. We can expand our manufacturing capabilities so that we can seamlessly produce additional product as market demand increases."

Ms. Kingston closed by emphasizing, "Part of our goal is to help consumers better understand immune health and how they can improve their energy level, biological responses, physical appearance, and even mood by supporting their immune system. Extensive clinical research has demonstrated that PURACERE™, the active ingredient in our new product lines, is a naturally powerful immunomodulator. The new iNR Wellness, iNR Wellness MD, and iNR Strength products can provide benefits to consumers regardless of the current state of their immune health."

iNR Wellness, iNR Wellness MD, and iNR Strength all contain the active ingredient PURACERE™. PURACERE is a proprietary, clinically researched, doctor-recommended, yeast beta 1,3/1,6-D-glucan. PURACERE is the purist yeast beta-glucan available. Unlike many other immune support dietary supplements, PURACERE does not contain any yeast by-products, endotoxins, excessive proteins, or ash. PURACERE has been clinically proven to prime the immune system and support immune health.

About ImmuDyne

ImmuDyne is a scientific-based, wellness company. Since 1990, ImmuDyne has been providing value to consumers with our extensively researched, ultrapure, proprietary yeast beta-1,3/1,6-D-glucan supplements. ImmuDyne has a portfolio of unique proprietary and patent-protected products with applications in the wellness, skin care, anti-aging, fitness, and health markets. ImmuDyne has offices located in Mt. Kisco, NY, Carlsbad, CA, and Florence, Kentucky. PURACERE, iNR Strength, iNR Wellness, and iNR Wellness MD are trademarks of ImmuDyne, Inc. 2013.

ImmuDyne shares trade under the ticker symbol IMMD and the Company can be found on the web at www.immudyne.com .

Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.

ImmuDyne, Inc. Mark McLaughlin +1-914-714-8901

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 7

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 8

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 2

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 6

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 4

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 2

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 3

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 4

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 2

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 9

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading

Top 5 Most Recently Viewed Articles

Earnings Season Highlights: Constellation, Delta, and Walgreens

Updated Category News Views 182

Earnings Season Highlights: Key Companies Preparing to Report The financial markets are buzzing as earnings season continues. This is an exciting time for investors and analysts alike as companies unveil their financial performance. On the horizon are a few major players that are set to announce their earnings. Notably, Constellation Brands (NYSE: STZ), Delta Air Lines...

Continue Reading
Mitek Plans Conference Call for Fiscal First Quarter Results

Updated Category News Views 98

Mitek Plans Conference Call for Fiscal First Quarter Results Mitek Systems, Inc. (NASDAQ: MITK), a leading player in digital identity verification and mobile capture technologies, is set to announce its financial results for the first quarter of the fiscal year. The financial information will be publicly released on an upcoming Monday, shortly before a conference call...

Continue Reading
ABN AMRO and Blackstone Forge Strategic Risk Transfer Deal

Updated Category News Views 191

ABN AMRO and Blackstone Collaborate on Risk Management In a notable development in the financial sector, ABN AMRO has successfully executed a significant risk transfer (SRT) transaction with funds managed by Blackstone. This strategic collaboration aims to enhance ABN AMRO's growth potential while effectively managing substantial corporate loan portfolios. The...

Continue Reading
Analyzing Williams Companies: P/E Insights and Implications

Updated Category News Views 113

Understanding the P/E Ratio of Williams Companies Currently, the stock of Williams Companies Inc. is trading at $59.89, reflecting a 0.40% increase in its price. Over the past month, the stock has surged by 15.07%, and in the past year, it has shown impressive growth of 64.19%. Such substantial performance has left long-term shareholders feeling quite optimistic. However,...

Continue Reading
Miami International Holdings Set to Launch Futures Trading Soon

Updated Category News Views 242

Miami International Holdings Plans Financial Futures Launch Miami International Holdings, Inc. (NYSE: MIAX) is gearing up to enhance its trading platform with the introduction of financial futures on MIAX Futures™. This strategic move marks a significant milestone for the company and is anticipated to offer traders new and exciting opportunities. Overview of MIAX...

Continue Reading